JP2019523001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523001A5 JP2019523001A5 JP2019503538A JP2019503538A JP2019523001A5 JP 2019523001 A5 JP2019523001 A5 JP 2019523001A5 JP 2019503538 A JP2019503538 A JP 2019503538A JP 2019503538 A JP2019503538 A JP 2019503538A JP 2019523001 A5 JP2019523001 A5 JP 2019523001A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- transduced
- culturing
- heterologous nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366493P | 2016-07-25 | 2016-07-25 | |
| US62/366,493 | 2016-07-25 | ||
| PCT/US2017/043774 WO2018022646A1 (en) | 2016-07-25 | 2017-07-25 | Methods of producing modified natural killer cells and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523001A JP2019523001A (ja) | 2019-08-22 |
| JP2019523001A5 true JP2019523001A5 (enExample) | 2020-08-06 |
| JP7086928B2 JP7086928B2 (ja) | 2022-06-20 |
Family
ID=59656171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503538A Active JP7086928B2 (ja) | 2016-07-25 | 2017-07-25 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
| JP2020524196A Active JP7364559B2 (ja) | 2016-07-25 | 2018-11-01 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524196A Active JP7364559B2 (ja) | 2016-07-25 | 2018-11-01 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11293010B2 (enExample) |
| EP (2) | EP3487991B1 (enExample) |
| JP (2) | JP7086928B2 (enExample) |
| CN (2) | CN109844099B (enExample) |
| IL (1) | IL273979B2 (enExample) |
| SG (2) | SG11201810871WA (enExample) |
| WO (2) | WO2018022646A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| WO2016077734A2 (en) * | 2014-11-14 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors |
| SG11201810871WA (en) | 2016-07-25 | 2019-01-30 | Us Health | Methods of producing modified natural killer cells and methods of use |
| US12516292B2 (en) | 2016-07-25 | 2026-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing modified natural killer cells and methods of use |
| WO2018104554A1 (en) * | 2016-12-09 | 2018-06-14 | Onkimmune Limited | Improved nk-based cell therapy |
| JP2020507349A (ja) | 2017-02-09 | 2020-03-12 | インダプタ セラピューティクス インコーポレイテッド | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
| AU2018245749A1 (en) | 2017-03-27 | 2019-10-03 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| JP7268039B2 (ja) | 2018-02-01 | 2023-05-02 | エヌケーマックス カンパニー リミテッド | がん治療のためのナチュラルキラー細胞および組成物の製造方法 |
| SG11202007156QA (en) * | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019165097A1 (en) * | 2018-02-21 | 2019-08-29 | Board Of Regents,The University Of Taxas System | Universal antigen presenting cells and uses thereof |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| AU2019271366B2 (en) * | 2018-05-16 | 2026-02-26 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins |
| EP3796934A4 (en) * | 2018-05-23 | 2022-04-06 | Manysmart Therapeutics, Inc. | BISPECIFIC T-LYMPHOCYTE ACTIVATOR AND USES THEREOF |
| CN112204133B (zh) * | 2018-05-30 | 2024-04-19 | 格雷克斯迪姆医疗私人有限公司 | Car nk细胞 |
| CN112469816A (zh) * | 2018-06-06 | 2021-03-09 | 加拿大干细胞技术公司 | 用于富集髓系来源的抑制细胞的试剂盒、组合物和方法 |
| JP7241161B2 (ja) | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| SG11202101996QA (en) * | 2018-08-28 | 2021-03-30 | Immunotech Biopharm Co Ltd | Improved therapeutic t cell |
| US20220042039A1 (en) * | 2018-08-28 | 2022-02-10 | Pharos Vaccine Inc. | Improved lentiviral vector |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| CN110511912B (zh) * | 2018-08-30 | 2024-03-22 | 浙江煦顼技术有限公司 | 免疫细胞的功能调节 |
| WO2020077091A1 (en) * | 2018-10-10 | 2020-04-16 | Wisconsin Alumni Research Foundation | Kir 7.1 gene therapy vectors and methods of using the same |
| CN109402053A (zh) * | 2018-10-17 | 2019-03-01 | 广州元帅生物科技有限公司 | 一种外周血来源单个核细胞的分离及诱导培养方法 |
| CN113891934A (zh) * | 2018-11-21 | 2022-01-04 | 因达普塔治疗公司 | 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法 |
| CA3131879A1 (en) * | 2019-02-20 | 2020-08-27 | Rutgers, The State University Of New Jersey | Expansion of natural killer and chimeric antigen receptor-modified cells |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| EP3938387A1 (en) | 2019-03-15 | 2022-01-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| KR20200110576A (ko) * | 2019-03-15 | 2020-09-24 | 재단법인대구경북과학기술원 | 사이토카인 기반 면역세포 및 그의 면역 치료 용도 |
| AU2020242305A1 (en) * | 2019-03-21 | 2021-09-30 | Onk Therapeutics Limited | Modified immune effector cells with increased resistance to cell death |
| EP3712257A1 (en) * | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| CN110079529A (zh) * | 2019-04-28 | 2019-08-02 | 成都美杰赛尔生物科技有限公司 | 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途 |
| CN110106202A (zh) * | 2019-05-07 | 2019-08-09 | 杭州师范大学 | 抗肿瘤nk细胞的制备方法及其细胞与应用 |
| US20210008110A1 (en) * | 2019-06-14 | 2021-01-14 | Serhat Gumrukcu | Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions |
| CN110205293A (zh) * | 2019-06-25 | 2019-09-06 | 中冠赛尔生物科技(北京)有限公司 | 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用 |
| WO2021051088A1 (en) * | 2019-09-13 | 2021-03-18 | Ohio State Innovation Foundation | Nk cell immunotherapy compositions, methods of making and methods of using same |
| US20210077527A1 (en) * | 2019-09-13 | 2021-03-18 | The Research Institute At Nationwide Children's Hospital | Universal donor selection method to identify nk-cell-donors |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| US20230190800A1 (en) | 2020-03-26 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Cd28h domain-containing chimeric antigen receptors and methods of use |
| CN113528452B (zh) * | 2020-07-06 | 2023-06-06 | 上海鑫湾生物科技有限公司 | 共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用 |
| KR20230058167A (ko) * | 2020-09-02 | 2023-05-02 | 엔카르타, 인크. | 조작된 자연 살해 세포의 향상된 증폭 및 세포 독성 및 그의 용도 |
| EP3964265A1 (en) * | 2020-09-07 | 2022-03-09 | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof |
| CN112029721A (zh) * | 2020-09-09 | 2020-12-04 | 广东昭泰体内生物医药科技有限公司 | 一种活性增强型nk细胞的制备方法 |
| KR102581230B1 (ko) * | 2020-10-16 | 2023-09-21 | 의료법인 성광의료재단 | 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도 |
| EP4240829A1 (en) | 2020-11-04 | 2023-09-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Modified nk cells with reduced ccr5 expression and methods of their use |
| EP4326288A1 (en) * | 2021-04-21 | 2024-02-28 | Indapta Therapeutics, Inc. | Methods of treatment and dosing of natural killer cell compositions |
| CN115505572B (zh) * | 2021-06-22 | 2025-11-14 | 康立泰生物医药(青岛)有限公司 | 一种增强型抗肿瘤nk细胞及其制备方法和应用 |
| AU2022340720A1 (en) * | 2021-08-30 | 2025-03-06 | Carrygenes Bioengineering, Llc | Use of growth factors for t cell activation |
| WO2023044304A1 (en) | 2021-09-15 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| CN114306606B (zh) * | 2021-11-29 | 2023-05-26 | 江苏省人民医院（南京医科大学第一附属医院） | cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用 |
| CN114381434A (zh) * | 2022-01-17 | 2022-04-22 | 华东师范大学 | 一种趋化型car-nk细胞及其制备方法和应用 |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
| CN115074325A (zh) * | 2022-07-07 | 2022-09-20 | 广州希灵生物科技有限公司 | Herceptin联合4-1BBL体外扩增NK方法 |
| CN115466726B (zh) * | 2022-09-05 | 2023-09-19 | 北京景达生物科技有限公司 | 一种nk细胞的高效基因转导方案 |
| CN116178566A (zh) * | 2022-09-30 | 2023-05-30 | 深圳博雅感知药业有限公司 | 靶向cd33的嵌合抗原受体和制备b16-cd33 car-nk细胞的方法 |
| CN115975922B (zh) * | 2022-12-15 | 2024-06-28 | 杭州师范大学 | Bx795在制备nk-92细胞激活剂上的应用 |
| CN120344655A (zh) * | 2022-12-19 | 2025-07-18 | 苏州沙砾生物科技有限公司 | 一种细胞培养方法及其用途 |
| CN121358493A (zh) | 2023-06-20 | 2026-01-16 | 泽卢纳免疫疗法公司 | 增强或修饰nk细胞的方法 |
| WO2025232819A1 (en) * | 2024-05-08 | 2025-11-13 | Qihan Hong Kong Limited | Immunotherapies using engineered cells for enhanced bone marrow homing |
| EP4692325A1 (en) * | 2024-08-07 | 2026-02-11 | Miltenyi Biotec B.V. & Co. KG | Method for generation of a composition comprising natural killer cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| DE10019075B4 (de) * | 2000-04-18 | 2007-01-18 | Vision 7 Gmbh | Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20090104170A1 (en) | 2004-11-02 | 2009-04-23 | Richard William Wyatt Childs | Compositions and methods for treating hyperproliferative disorders |
| CN101356679A (zh) * | 2005-10-31 | 2009-01-28 | 昂考梅德药品有限公司 | 用于诊断和治疗癌症的组合物和方法 |
| US20070264687A1 (en) * | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| CN101684456A (zh) * | 2008-09-28 | 2010-03-31 | 江门罗森生物制药有限公司 | 一种体外培养条件下扩增人nk细胞的方法 |
| WO2010148203A2 (en) * | 2009-06-17 | 2010-12-23 | Tocagen Inc. | Producer cells for replication competent retroviral vectors |
| CN112458057A (zh) * | 2012-10-02 | 2021-03-09 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| EP2793026A1 (en) * | 2013-04-18 | 2014-10-22 | Centre National de la Recherche Scientifique (CNRS) | New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation |
| BR112015027567B1 (pt) * | 2013-05-03 | 2024-02-20 | Ohio State Innovation Foundation | Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula |
| WO2015112793A2 (en) * | 2014-01-27 | 2015-07-30 | St. Jude Children's Research Hospital, Inc. | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof |
| WO2016073595A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| WO2016077734A2 (en) | 2014-11-14 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors |
| US10815457B2 (en) * | 2014-11-24 | 2020-10-27 | University Of Pittsburgh Of The Commonwealth Systems Of Higher Education | Active CXCR4+ immune cells and methods for their production and use |
| PT3356524T (pt) * | 2015-09-30 | 2021-11-17 | Vycellix Inc | Distribuição melhorada de genes a células assassinas naturais, células estaminais hematopoéticas e macrófagos |
| CN105567634A (zh) * | 2016-01-27 | 2016-05-11 | 上海润泉生物技术有限公司 | 一种用于nk细胞体外扩增的培养基及nk细胞体外扩增的方法 |
| US12516292B2 (en) * | 2016-07-25 | 2026-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing modified natural killer cells and methods of use |
| SG11201810871WA (en) | 2016-07-25 | 2019-01-30 | Us Health | Methods of producing modified natural killer cells and methods of use |
| CN106350487B (zh) * | 2016-09-13 | 2019-01-25 | 北京多赢时代转化医学研究院 | 联合制备car-nk细胞和car-nkt细胞的方法 |
| WO2018098279A1 (en) * | 2016-11-22 | 2018-05-31 | Alloplex Biotherapeutics | Allogenic tumor cell vaccine |
-
2017
- 2017-07-25 SG SG11201810871WA patent/SG11201810871WA/en unknown
- 2017-07-25 CN CN201780046354.1A patent/CN109844099B/zh active Active
- 2017-07-25 JP JP2019503538A patent/JP7086928B2/ja active Active
- 2017-07-25 EP EP17754517.5A patent/EP3487991B1/en active Active
- 2017-07-25 WO PCT/US2017/043774 patent/WO2018022646A1/en not_active Ceased
- 2017-11-01 US US15/801,085 patent/US11293010B2/en active Active
-
2018
- 2018-11-01 JP JP2020524196A patent/JP7364559B2/ja active Active
- 2018-11-01 EP EP18811415.1A patent/EP3704231A1/en active Pending
- 2018-11-01 WO PCT/US2018/058747 patent/WO2019089955A1/en not_active Ceased
- 2018-11-01 IL IL273979A patent/IL273979B2/en unknown
- 2018-11-01 SG SG11202003201QA patent/SG11202003201QA/en unknown
- 2018-11-01 CN CN201880071474.1A patent/CN111344395B/zh active Active
-
2022
- 2022-03-07 US US17/688,435 patent/US12448604B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523001A5 (enExample) | ||
| JP2021501578A5 (enExample) | ||
| Liu et al. | NK cell-based cancer immunotherapy: from basic biology to clinical development | |
| Zhang et al. | Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside | |
| Shimasaki et al. | Expanded and armed natural killer cells for cancer treatment | |
| JP7778708B2 (ja) | 多能性幹細胞からナチュラルキラー細胞を産生するための方法 | |
| IL273979B2 (en) | Methods of producing modified natural killer cells and methods of use | |
| JP2022130607A (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| Meng et al. | Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells | |
| Murad et al. | Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy | |
| CN114761027A (zh) | 用于免疫细胞扩增的Cbl抑制剂和组合物 | |
| JP6971986B2 (ja) | 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞 | |
| CN118813544A (zh) | 遗传修饰的自然杀伤细胞 | |
| Zhang et al. | Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS− regulatory T cells | |
| JP2022542321A (ja) | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 | |
| Shook et al. | Natural killer cell engineering for cellular therapy of cancer | |
| CN115768879A (zh) | 用于培养细胞的方法 | |
| Xu et al. | Cellular immunotherapy for hematological malignancy: recent progress and future perspectives | |
| CN113785048B (zh) | 用于扩增和分化在过继转移疗法中的t淋巴细胞和nk细胞的方法 | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| CN107002036A (zh) | 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法 | |
| JP2018531016A5 (enExample) | ||
| Payne et al. | Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy | |
| Han et al. | Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies | |
| Fukuta et al. | Cell therapies against brain tumors: Clinical development and emerging prospects |